Low-Frequency Hearing Loss Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process — Editorial Process Last reviewed: 2026-05-25

This page is informational only. For health decisions, consult a qualified clinician.

Low-frequency hearing loss is difficulty hearing deeper sounds — low-pitched voices, bass tones, and background rumble — that can develop with age. Genomic studies have identified genetic signals for this pattern that are partly distinct from those driving high-frequency hearing decline. TRIOBP and other genes with inner ear roles appear in the associated genomic regions. Below: the biology behind low-frequency hearing loss, the genetic signals identified, and what current research supports about this less-common pattern of age-related hearing change.

What is low-frequency hearing loss?

Low-frequency hearing loss is difficulty perceiving sounds below about 2,000 Hz — including the lower register of human speech, bass tones, and deeper environmental sounds.

It is less common than high-frequency hearing loss, which is the most typical pattern of age-related hearing change. When it occurs as an age-related phenomenon, low-frequency loss may involve changes at the cochlear apex — the region of the cochlea tuned to process lower-pitched sounds. The genetic architecture of low-frequency hearing decline appears partly distinct from that of high-frequency loss, suggesting that different biological pathways contribute to which frequency range is affected first and most significantly. (Wells et al. 2019)

People with low-frequency loss may notice changes in how they perceive the fundamental pitch of voices, the resonance of music, or deeper environmental sounds — rather than the consonant-clarity difficulties typical of high-frequency patterns.

The genetics behind low-frequency hearing loss

Large population genomic studies examining frequency-specific hearing outcomes have found that the genetic signals for low- and mid-frequency hearing change do not fully overlap with those for high-frequency hearing. Different loci reach significance when the analysis is restricted to lower-frequency outcomes, suggesting distinct — though overlapping — genetic architectures between frequency ranges. (Wells et al. 2019)

The gene with the strongest established biological connection to hearing in the regions associated with this trait is TRIOBP (Trio and F-Actin Binding Protein). TRIOBP is expressed in cochlear hair cells, where it organizes the actin cytoskeleton of the stereocilia — the microscopic hair-like projections that physically vibrate in response to sound waves and initiate the hearing signal. Rare, severely damaging mutations in TRIOBP cause DFNB28, a form of autosomal recessive nonsyndromic hearing loss. The common variation near this locus that appears in this trait’s genetic profile reflects population-level differences in the associated genomic region, carrying a far more modest effect than the rare disease-causing mutations.

ACAN (Aggrecan) encodes a major structural proteoglycan of the cartilaginous extracellular matrix and is well-characterized in skeletal and cartilage biology. Its presence in this trait’s associated data likely reflects proximity to a causal signal at the locus rather than a direct role in cochlear function — the specific causal relationship, if any, to low-frequency hearing at the population level remains to be established through fine-mapping studies.

SPTBN1 (Spectrin Beta Non-Erythrocytic 1) encodes a cytoskeletal scaffolding protein with expression in neurons and hair cells. Spectrin proteins contribute to the structural integrity of cell membranes, and neuronal spectrin function is relevant to auditory nerve signaling. The population-level contribution of SPTBN1 variation to this specific hearing pattern remains under investigation. Additional genes in the associated regions include FXYD5, a membrane regulatory protein, and FAM187B, for which functional annotation is currently limited.

High-frequency and low-frequency hearing loss have partly distinct genetic profiles — identified through large-scale genomic studies that examined frequency-specific hearing outcomes separately. Different loci reach statistical significance depending on which frequency range is the primary outcome. (Wells et al. 2019)

TRIOBP is the gene with the most established biological connection to cochlear function in the genomic regions associated with this trait — known for its role in organizing stereocilia structure in cochlear hair cells, with rare mutations causing a recognized form of hereditary hearing loss.

What the research says

Research base: Moderate. Population genomic studies have identified loci associated with low- and mid-frequency hearing outcomes in large cohorts. The evidence meets the threshold for a supported genetic association at the trait level. However, the causal genes at individual loci are less definitively characterized than for high-frequency hearing loss, and fine-mapping to specific causal variants within these regions is ongoing.

Low-frequency hearing loss has been studied somewhat less extensively than high-frequency loss in the genomic literature, in part because high-frequency decline is the more prevalent pattern and has attracted more research focus. The separation of frequency-specific outcomes in large biobank studies is a relatively recent development, enabling more precise characterization of the genetic factors behind each pattern. (Wells et al. 2019)

The total heritability of hearing change is substantial; however, the portion explained by any single genetic signal is modest. Environmental factors — including cardiovascular health, medication exposure, and inner ear fluid dynamics — contribute significantly to who develops low-frequency hearing change and at what rate. See our methodology page for the statistical approach behind this profile.

How low-frequency hearing loss affects you

Low-frequency hearing loss affects different aspects of hearing than the more common high-frequency pattern. Rather than struggling primarily with speech clarity in noisy environments, people with low-frequency loss may notice changes in how they perceive the fundamental pitch of voices, the resonance and depth of sounds, and music — particularly bass tones and the lower harmonics that give sound its sense of warmth and body.

Because the fundamental frequencies of human speech — the voiced, resonant quality of vowels — fall partly in the low- and mid-frequency range, significant low-frequency loss can affect the naturalness and richness of speech perception even if high-frequency consonant clarity is preserved. Someone might notice that voices sound thinner or less resonant rather than having trouble distinguishing words in noise, which is the more typical complaint with high-frequency loss.

Low-frequency hearing loss is less common as an isolated finding and is sometimes associated with conditions that affect inner ear fluid dynamics. When it co-occurs with high-frequency loss across a broader range of frequencies, the combined effect on speech understanding can be more significant than either pattern alone.

Factors that influence low-frequency hearing health

Several variables interact with genetic predisposition to shape hearing across all frequency ranges, including low frequencies:

• Inner ear fluid dynamics — low-frequency hearing depends on the mechanical properties of the cochlear apex; conditions affecting inner ear fluid pressure can specifically impair this frequency range
• Cardiovascular health — the cochlea depends on healthy blood supply throughout its full length, including the apical region that processes lower pitches; vascular impairment affects cochlear function across frequencies
• Loop diuretics and certain medications — some medications, particularly loop diuretics used to manage blood pressure and fluid retention, can affect low-frequency hearing specifically as a known side effect
• Age — the cochlear apex, like the entire cochlear frequency map, undergoes biological aging; the rate differs between individuals and is shaped by both genetics and lifetime exposures
• Underlying systemic conditions — autoimmune conditions and metabolic disorders can affect inner ear function across frequency ranges

Working with your low-frequency hearing profile

A genetic signal for elevated susceptibility to low-frequency hearing loss is context for awareness, not a predetermined outcome. The following steps are practical for anyone with this profile:

Evidence-backed steps

1. Get a full-frequency audiogram. Standard audiometry tests hearing thresholds across the speech frequency range — including low, mid, and high frequencies. If low-frequency patterns are present, this evaluation will document them and provide a baseline for future comparison.
2. Mention this trait to your audiologist or clinician. Low-frequency hearing loss has specific patterns and causes that differ from high-frequency loss; a clinician aware of your family history and genetic profile can tailor evaluation and monitoring accordingly.
3. Know your medication history. If you take loop diuretics (such as furosemide) or other medications with known effects on low-frequency hearing, discuss monitoring with your prescribing clinician, particularly if you notice muffling of bass tones or voices.
4. Prioritize cardiovascular health. Vascular health is a major modifiable contributor to cochlear function across all frequency ranges. Regular exercise, blood pressure management, and not smoking each carry independent associations with better long-term hearing outcomes.
5. Report sudden or fluctuating hearing changes promptly. Sudden or rapidly varying low-frequency hearing loss warrants prompt audiological evaluation, as some causes are treatable if addressed quickly.
6. Monitor proactively if changes are noticed. If music sounds thinner than it used to, deeper voices seem less clear, or the resonance of sounds has changed, audiometric evaluation can clarify whether low-frequency thresholds are shifting.

Related traits and genes

Low-frequency hearing loss is one component of ExomeDNA’s hearing genetics assessment. Related traits include:

• High-Frequency Hearing Loss Risk — the most common age-related hearing pattern follows partly distinct genetic pathways; comparing your high- and low-frequency profiles reveals whether your variants point toward frequency-specific or broader hearing susceptibility
• Tinnitus Susceptibility — ringing or persistent tones often co-occur with hearing loss patterns and may share biological contributors in cochlear or auditory nerve function
• Age-Related Hearing Loss — broader hearing decline assessment that captures overall auditory aging trajectories across frequency ranges

Cross-category traits with shared biology:

• Cardiovascular Disease Risk — cochlear vascular health is a key bridge between cardiovascular status and hearing outcomes; both profiles together provide more actionable context
• Joint and Cartilage Health — ACAN, a gene in the associated genomic regions, is primarily known for its role in cartilage extracellular matrix; the broader biology of this gene may be of interest alongside this hearing profile

Frequently asked questions

What is the difference between low-frequency and high-frequency hearing loss?

High-frequency hearing loss — the most common age-related pattern — primarily affects consonant sounds, speech clarity in noisy environments, and higher-pitched tones. Low-frequency hearing loss affects the ability to perceive deeper sounds: the fundamental pitch of voices, bass tones, and resonance. These patterns can occur separately or together and have partly distinct genetic profiles in large population genomic studies, which is why ExomeDNA reports them as separate traits.

What genes are associated with low-frequency hearing loss?

TRIOBP is the gene with the strongest established biological connection to hearing in the associated genomic regions. It encodes a protein that organizes the actin cytoskeleton of cochlear hair cell stereocilia, and rare mutations in it cause a recognized form of hereditary hearing loss (DFNB28). Other genes in the associated regions — including ACAN, SPTBN1, and FXYD5 — have been identified through genomic analysis, but their specific roles in age-related low-frequency hearing change are less characterized. Fine-mapping studies are ongoing to better identify causal variants at these loci.

Is low-frequency hearing loss more serious than high-frequency hearing loss?

Neither pattern is inherently more serious — each affects different aspects of hearing and daily experience. High-frequency loss typically impairs speech clarity in noise; low-frequency loss may affect the depth and resonance of speech and music. Severity depends on degree, frequency range affected, and individual circumstances. Both warrant audiological evaluation when functionally noticeable.

Can low-frequency hearing loss improve on its own?

Sudden low-frequency hearing loss — particularly when it fluctuates — may partially recover in some cases, especially when associated with treatable inner ear conditions. Age-related low-frequency hearing decline due to cumulative cochlear change does not typically reverse. Any sudden or rapidly worsening hearing change should be evaluated promptly, as some causes respond to treatment if addressed quickly.

What should I do if my profile shows elevated low-frequency hearing susceptibility?

A genetic signal for elevated susceptibility is context for proactive awareness, not a clinical emergency. Practical steps include baseline audiometry to document current hearing thresholds by frequency, attention to cardiovascular health as a key modifiable contributor to cochlear function, awareness of medication exposures with ototoxic potential for low frequencies, and prompt evaluation of any sudden or unexpected hearing changes. An audiologist can help interpret your specific pattern and recommend appropriate monitoring.

Wellness Information. ExomeDNA provides educational interpretation of genetic variants for general wellness purposes only. This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. Consult a healthcare provider before making medical decisions. See our methodology and test limitations for details.

References

1. Wells HR, Freidin MB, Zainul Abidin FN, et al. (2019). GWAS identifies 44 independent associated genomic loci for self-reported adult hearing difficulty in UK Biobank. American Journal of Human Genetics, 105(4), 788–802. PMID: 31645637.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-25)
• Open Targets Platform (CC0 1.0, accessed 2026-05-25)
• ClinVar (NCBI, accessed 2026-05-25) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-25)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-25.